



New Economic Model Shows Significant Cost Savings when using Cellvizio® to Ascertain Diagnosis of Benign Pancreatic Cysts

*Study shows a 23% reduction in surgical interventions
resulting in 14% reduction in clinical costs*

Paris and Boston, October 11, 2017 – 5.45 PM CET – Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced the publication of a new study highlighting significant potential cost savings in a French economic model when diagnosing pancreatic cysts with Cellvizio.

The study titled, “A health economic evaluation of needle-based Confocal Laser Endomicroscopy for the diagnosis of pancreatic cysts,” was published on October 9, 2017 in *Endoscopy International Open*, a peer-reviewed, open access journal in the field of gastrointestinal endoscopy. The study was led by Claude Le Pen, Professor of Health Economics at the Paris-Dauphine University, in Paris, France.

The study evaluated the health economic benefit of the diagnosis of benign cysts with Endoscopic Ultrasound and Fine Needle Aspiration (EUS-FNA) plus needle-based CLE with Cellvizio, compared to the standard of care of EUS-FNA alone. Several clinical studies have shown that visualization of specific cell patterns in real-time through optical biopsy with Cellvizio enables a more confident diagnosis leading to improved diagnostic accuracy.

Pr. Le Pen measured the benefit of utilizing Cellvizio in terms of the overall cost of procedures and hospital stays. Costs were estimated from the public payer's perspective, using French official tariffs. The study demonstrated that EUS-FNA plus Cellvizio results in significant economic benefits by reducing the incidence of misdiagnosis through improved diagnostic accuracy:

- 23% reduction in the total number of surgical interventions, which translated to a reduction in clinical costs of 13% (public sector) and 14% (private sector)
- Reduced rate of surgery, which would save the lives of 4 in 1,000 patients

Pr. Le Pen commented, “The addition of optical biopsy in conjunction with traditional diagnostic methods is an interesting scenario in the French healthcare system in which an adjunctive procedure can drive significant cost savings, but is not yet covered by reimbursement rules. Importantly, the cost savings are driven by improved clinical care for patients, which provides another compelling reason to adopt Cellvizio in the diagnosis of pancreatic cysts.”

Pr. Le Pen’s measure of the economic benefit of utilizing Cellvizio only takes into account the diagnostic procedure, the associated reduced rate of surgery, and the related costs associated with clinical intervention and hospital stay. It does not take into account potential additional economic benefit from improved diagnosis of benign cysts, which would likely reduce the number of repeated diagnostic procedures and the number of subsequent surveillance examinations, as well as reduce the number of re-hospitalizations and the amount of long-term treatment required following duodenopancreatectomy (Whipple’s surgery) or left pancreatectomy.

Sacha Loiseau, Ph.D., Founder and Chief Executive Officer of Mauna Kea Technologies, added, “Mauna Kea’s mission is to eliminate diagnostic and treatment uncertainties. This study shows, for the first time in pancreatic cysts, the economic and clinical advantages of utilizing Cellvizio to improve diagnostic accuracy. We hope this study will enable a change in healthcare practice for patients with pancreatic cysts and will bring providers a higher level of certainty on their diagnosis and treatment plans.”



About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company's flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico. For more information on Mauna Kea Technologies, visit www.maunakeatech.com

United States

Zack Kubow / Lee Roth
The Ruth Group
646-536-7020 / 7012
zkubow@theruthgroup.com lroth@theruthgroup.com

U.S. Media

Kirsten Thomas
The Ruth Group
508-280-6592
kthomas@theruthgroup.com

France and Europe

NewCap - Investor Relations
Florent Alba
+33 (0)1 44 71 94 94
maunakea@newcap.eu

Disclaimer

This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities. Such forward looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward-looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of Mauna Kea Technologies registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on June 13, 2016 under number R.16-054 and available on the Company's website (www.maunakeatech.com), and to the development of economic situation, financial markets, and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Mauna Kea Technologies that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for, Mauna Kea Technologies shares in any country.